Thousands of elderly patients in Canada are being treated with an antipsychotic now involved in heated Risperdal lawsuit litigation, which may be harmful to their health.
According to an article published February 14th in the OttowaCitizen.com, 31.7% of 7,500 long-term home care patients within the Champlain Local Health Integration Network (LHIN) are given Risperdal and other medications without diagnoses for psychotic conditions. According to the report, Ottawa and most of the Eastern Ontario region are included in this network.
The treatment of aggressive behavior in dementia patients, as well as its use in controlling agitation in patients with the condition is considered by the Canadian Institute for Health Information as a “potentially inappropriate” use of medication.
According to a geriatric psychiatrist at the Royal Ottawa Mental Health Centre, only a small percentage of these individuals may see positive results from Risperidone, also marketed under its brand name as Risperdal) and aripiperazole.
The others may not benefit from the medication, which has been allegedly associated with breast growth in a number of Risperdal gynecomastia lawsuit filings. According to the psychiatrist, 60 percent of long-term care residents have dementia, and only half may experience aggressive behavior or agitation.
“In reality, only six per cent of patients should be on antipsychotics,” he said. “The others are no better.”
One woman quoted in the OttowaCitizen.com says she is now an advocate for the care of her husband, a dementia patient, after learning of side effects associated with this class of medications.
“Why are we doing this to the most vulnerable people in our society?” she asks.
The woman adds that she had to take him to the emergency room twice at the end of October. The first was for a fall, and the second was for “terrible pain” in his legs.
Meanwhile, other side effects have been alleged in more than 200 Risperdal lawsuit filings now pending in the Philadelphia Court of Common Pleas. In a consolidated litigation established in Pennsylvania state court, numerous claims of gynecomastia, a condition categorized for male breast development, have been filed in this consolidated Pennsylvania litigation, court documents indicate.
Start the process of filing a Risperdal lawsuit with an attorney at Bernstein Liebhard LLP. You may be eligible to receive compensation for damages allegedly caused by your injury. Our Firm’s attorneys can be reached at .